Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SANCUSO | Cumberland Pharmaceuticals | N-022198 RX | 2008-09-12 | 1 products, RLD, RS |
SUSTOL | Heron Therapeutics | N-022445 RX | 2016-08-09 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
granisetron | ANDA | 2019-12-31 |
granisetron hydrochloride | ANDA | 2024-01-04 |
sancuso | New Drug Application | 2023-08-24 |
sustol | New Drug Application | 2023-06-07 |
Code | Description |
---|---|
J1626 | Injection, granisetron hydrochloride, 100 mcg |
J1627 | Injection, granisetron, extended-release, 0.1 mg |
Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
S0091 | Granisetron hydrochloride, 1 mg (for circumstances falling under the medicare statute, use q0166) |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vomiting | D014839 | HP_0002013 | R11.1 | 4 | 8 | 15 | 6 | 10 | 43 |
Nausea | D009325 | HP_0002018 | R11.0 | 2 | 2 | 3 | 4 | 4 | 15 |
Neoplasms | D009369 | — | C80 | 2 | 2 | 5 | 1 | 2 | 12 |
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | 2 | 3 | 4 | 2 | 11 |
Lymphoma | D008223 | — | C85.9 | — | 2 | — | 1 | 1 | 4 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | 1 | 1 | 3 |
Leukemia | D007938 | — | C95 | — | — | — | 1 | 1 | 2 |
Prostatic neoplasms | D011471 | — | C61 | — | — | — | 1 | — | 1 |
Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | 1 | — | 1 |
Temporomandibular joint disorders | D013705 | — | M26.6 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | — | 1 | — | 1 | 2 |
Hypotension | D007022 | EFO_0005251 | I95 | — | — | 1 | — | 1 | 2 |
Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | 1 | — | — | 2 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | 1 | — | — | 1 |
Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | — | I77.82 | — | — | 1 | — | — | 1 |
Postoperative complications | D011183 | — | — | — | — | 1 | — | — | 1 |
Intraoperative complications | D007431 | — | — | — | — | 1 | — | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
Mantle-cell lymphoma | D020522 | — | C83.1 | — | 1 | — | — | — | 1 |
Mast-cell leukemia | D007946 | — | C94.3 | — | 1 | — | — | — | 1 |
Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | — | — | — | 1 |
Pruritus | D011537 | HP_0000989 | L29 | — | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Drug therapy | D004358 | — | — | — | 1 | — | — | — | 1 |
Postoperative pain | D010149 | — | G89.18 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 9 | — | — | — | 1 | 10 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tick-borne encephalitis | D004675 | EFO_1001309 | A84 | — | — | — | — | 3 | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 2 | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
Brenner tumor | D001948 | — | — | — | — | — | — | 1 | 1 |
Endometrioid carcinoma | D018269 | — | — | — | — | — | — | 1 | 1 |
Fallopian tube neoplasms | D005185 | — | — | — | — | — | — | 1 | 1 |
Cystadenocarcinoma | D003536 | — | — | — | — | — | — | 1 | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | — | — | — | — | 1 | 1 |
Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 1 | 1 |
Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | — | 1 | 1 |
Drug common name | Granisetron |
INN | granisetron |
Description | 1-Methyl-N-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1H-indazole-3-carboxamide is a member of indazoles and an aromatic amide. |
Classification | Small molecule |
Drug class | serotonin 5-HT3 receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2 |
PDB | — |
CAS-ID | 107007-99-8 |
RxCUI | — |
ChEMBL ID | CHEMBL289469 |
ChEBI ID | — |
PubChem CID | 3510 |
DrugBank | DB00889 |
UNII ID | WZG3J2MCOL (ChemIDplus, GSRS) |